Agnostic metagenomic next-generation sequencing (mNGS) has emerged as a promising single, universal pathogen detection method for infectious disease diagnostics. This methodology allows for identification and genomic characterization of bacteria, fungi, parasites, and viruses without the need for a priori knowledge of a specific pathogen directly from clinical specimens. Although there are increasing reports of mNGS successes, several hurdles need to be addressed, such as differentiation of colonization from infection, extraneous sources of nucleic acid, method standardization, and data storage, protection, analysis, and interpretation. As more commercial and clinical microbiology laboratories develop mNGS assays, it is important for treating practitioners to understand both the power and limitations of this method as a diagnostic tool for infectious diseases.
Infectious diseases remain leading causes of morbidity and mortality among all patient populations worldwide [1] . The spread of multidrug-resistant pathogens such as Candida auris and carbapenemase-producing gram-negative organisms and the reemergence of Ebola and Zika viruses highlight the ongoing challenges with diagnosis and management of patients with infectious diseases. Accurate diagnosis can be challenging due to a wide variety of pathogens causing clinically indistinguishable diseases. Current methods, such as culture, nucleic acid amplification tests, and serologic assays, generally require the use of a battery of tests to attempt to establish a diagnosis. Often times these methods still rely on a growth amplification step of viable microorganisms in culture for identification and antimicrobial susceptibility testing that take a minimum of 48 hours for commonly encountered pathogens and longer for more fastidious organisms (up to weeks for more insidious pathogens such as fungi and mycobacteria). Novel technologies such as syndromic multiplex polymerase chain reaction (PCR) panels, 16S ribosomal DNA (16S rDNA) Sanger sequencing, and matrix-assisted laser desorption/ionization-time-of-flight mass spectrometry (MALDI-TOF MS) have decreased turnaround times and subsequently beneficially impacted patient care [2] . Despite these advances, the etiology of infectious diseases remains unknown in up to 60% of cases depending on the clinical syndrome [3, 4] . Missed diagnoses due to the limitations of current microbiologic methodologies drive the use of empiric broad-spectrum antibiotics preventing the use of targeted, curative therapies.
Recent advances and lower costs of next-generation sequencing (NGS) technologies, more rapid, user-friendly data analysis tools, and the creation of accurate, comprehensive databases has allowed for NGS applications to cross the divide from microbial research to diagnostic microbiology [4] . One such application, unbiased metagenomic next-generation sequencing (mNGS), has the capability to overcome limitations of current diagnostic tests allowing for hypothesis-free, culture-independent, pathogen detection directly from clinical specimens. This method allows for universal pathogen detection regardless of the type of microbe (viruses, bacteria, fungi, and parasites) and can even be applied for novel organism discovery, potentially enabling replacement of many targeted pathogen tests with a single mNGS assay ( Figure 1 ). As the availability of mNGS clinical diagnostic tests increases, it is important for treating practitioners to understand both its strengths and limitations as a tool for infectious disease diagnostics.
WHAT IS mNGS?
Next-generation sequencing technologies allow for sequencing of multiple individual DNA molecules in parallel regardless of composition, generating millions to billions of reads per instrument run. Reads are the basic element produced by DNA sequencing that are composed of a series of sequential bases (adenine, guanine, thymine, and cytosine) making up the DNA fragment, which can vary in size from small reads (75-600 bp) to long reads (1000-10 000s bp) depending on the sequencing technology. NGS overcomes many of the limitations of traditional Sanger sequencing, which requires targeted sequencing (preamplification of a known target, such as 16S rDNA) of a uniform or low-diversity sample (the sample ideally is composed of a single organism or a maximum of 3 organisms).
The most common applications of NGS in diagnostic microbiology laboratories ( Figure 2 ) include (1) whole-genome sequencing (sequencing and assembly of the genome of a pathogen of interest [eg, evaluating genetic relatedness during outbreak investigations, identification of new species]) [5] [6] [7] ; (2) targeted NGS with different methods for enrichment including amplification or probe hybridization (ie, 16S rDNA bacterial profiling or PCR amplification of other specified targets followed by NGS) [7, 8] ; or (3) mNGS (defined in more detail below) [9] . We refer the reader to other publications on this topic that summarize common terms and approaches used in DNA sequence analysis [10] , the different NGS technologies [11] [12] [13] , and the various NGS methods, bioinformatics tools [14] and clinical applications [10, 15] . This review will focus on mNGS for infectious disease diagnostic pathogen detection. Other applications of mNGS testing directly from specimens that are also not covered in this review include antimicrobial resistance gene and virulence gene detection, strain typing, and host immune response profiling [16] . mNGS, also known as unbiased or agnostic NGS or clinical metagenomics, is a method where all the nucleic acid (DNA and/ or RNA) of a specimen is sequenced in parallel. This results in isolation and amplification of both host and pathogen nucleic acid sequenced from the specimen (Figure 2 ). Additional sources of nucleic acid that may be concurrently sequenced include nucleic acid introduced at the time of collection, within collection tubes, from the environment, and in sequencing reagents. Due to these complexities and potential breadth of detection, interpretation of mNGS results directly from clinical specimens can be difficult and requires careful interpretation and consideration.
HOST NUCLEIC ACID AMPLIFICATION: A BURDEN OR AN ADVANTAGE?
As the majority of a specimen is of human origin and the human genome is much larger than that of microorganisms (1000 times larger than bacterial genomes), the results from mNGS from clinical specimens typically generate >99% host Figure 1 . Summary of the traditional timeline and workflow in diagnostic medical microbiology laboratories and the future state with the incorporation of metagenomic next-generation sequencing (mNGS) methodologies. Current organism detection techniques (orange), identification (yellow), antimicrobial susceptibility testing (green), and strain typing (purple) can take up to a week or longer from specimen collection (blue) to strain typing results. mNGS has the capability of greatly reducing turnaround times and providing all the data summarized in current methods in a single modality (red) and could potentially provide all of these within 24-48 hours of specimen receipt. To date, the available evidence is poor to use antibiotic resistance gene detection to predict phenotypic antimicrobial susceptibility testing profiles for clinical care [16] . Abbreviations: AFB, acid-fast bacilli; cDNA, complementary DNA; CSF, cerebrospinal fluid; KOH, potassium hydroxide; MALDI-TOF MS, matrix-assisted laser desorption/ionization-timeof-flight mass spectrometry; MLST, multilocus sequence typing; mNGS, metagenomic next-generation sequencing; PCR, polymerase chain reaction; PFGE, pulsed-field gel electrophoresis; 16S rDNA, 16S ribosomal DNA.
reads [17] . Successful clinical applications of mNGS have demonstrated that 0.00001%-0.7% of total reads (10 to tens of thousands of pathogen reads out of a total of millions of reads) have been used to make successful diagnoses (Table 1 , mNGS results column). Pathogen reads make up a minute fraction of the sequencing results. Host nucleic acid can be depleted [18] or, if pathogen reads are enriched, more microorganism reads can be generated to more confidently provide a diagnosis and allow for increased analytical sensitivity (limit of detection). Additionally, if a robust immune response is generated in response to the pathogen, the specimen will contain a high concentration of leukocytes, further contributing to host nucleic acid in the sample and further limiting pathogen detection. Thus, the higher the sequencing depth (the higher number of reads generated/specimen) of the method, the higher the likelihood that the pathogen will be sequenced and detected (more reads equals higher sensitivity). For a conceptual illustration of how cellularity and overall nucleic acid affect analytic sensitivity, see Figure 1 in Schlaberg et al [4] . One potential advantage of sequencing amplified host nucleic acid is the opportunity to evaluate the host immunologic response associated with the presence and type of infection. This can include the presence of gene biomarkers associated with an antiviral or antibacterial response (specific expression of cytokines, chemokines, interferons, etc), genes involved in signaling pathways, and adaptive immunity. These biomarkers can provide insight into the pathogenesis of the microorganisms detected [19] .
HOW TO DISCRIMINATE BETWEEN COLONIZATION AND INFECTION?
Detection of microorganisms in clinical samples by mNGS can reflect normal microbiota, transient colonizers, sample contamination, and/or infection. Initial applications of mNGS focused on detection of pathogens in normally sterile specimens, such as cerebrospinal fluid (CSF) and brain biopsies, simplifying the assignment of clinical significance for detected organisms [17, [20] [21] [22] [23] . That being said, even body sites that are considered normally "sterile" may contain a microbiome, which can be defined and detected by deep sequencing [24] . Reports in the literature are now showing applications from other specimen types where normal microbiota can further complicate interpretation of results, such as respiratory specimens [19, 25] . These methods will likely require further studies to determine the best approach to distinguish colonization from infection. Currently, mNGS is only able to quantify pathogen reads as a percentage of the total number of sequence reads. Clinical microbiology laboratories have developed procedures throughout the years to distinguish true pathogens from colonizers in cultures, and similar 
Neuroleptospirosis
Treated with a course of penicillin G and discharged after 1 month with mild neurologic deficits.
[22]
42-year-old man with chronic lymphocytic leukemia presented with bilateral hearing loss. He developed neurological deterioration.
1612 of 134 068 968 (0.0012%) reads from brain tissue RNA aligned to astrovirus, no astrovirus reads were obtained from the 6 658 656 reads from CSF.
RT-PCR for astrovirus from the brain biopsy

Neuroinvasive astrovirus infection
Treated empirically with high-dose valacyclovir, broad-spectrum antibiotics, and IVIG. After the NGS analysis revealed astrovirus, the patient was treated with ribavirin and IVIG but eventually passed away.
[35]
3 male (aged 63, 63, and 72 years) breeders of variegated squirrels had progressive encephalitis Variegated squirrel 1 bornavirus reads detected in brain samples from all 3 patients.
RT-qPCR
Variegated squirrel bornavirus encephalitis All 3 patients passed away prior to mNGS results.
[43]
11-year-old girl from Mexico presented with 4 weeks of headache, back pain, nausea, and emesis. CSF was found to be positive for EBV and HHV7. She was treated with acyclovir and discharged. Two weeks later she presented with back pain and worsening headache. She was rehospitalized with a diagnosis of tuberculosis. Brucella PCR and serologies
Chronic neurobrucellosis
Treated with a course of doxycycline and rifampin. Two weeks after starting therapy she reported that her symptoms fully resolved.
[21]
15-year-old girl with diabetes presented to an emergency department with 7 days of progressive symptoms including right arm weakness, headache, vomiting, ataxia, and confusion. She clinically deteriorated over 8 days where she developed intracranial hypertension and cardiac arrest and died. [17]
34-year-old Australian man with X-linked agammaglobulinemia suffering from 3 years of meningoencephalitis that defied an etiologic disease despite extensive conventional testing, including brain biopsy. [23]
16-year-old boy from Vietnam suddenly became ill with fevers and rigors, followed by back pain, diarrhea, neck stiffness, limb weakness with eventual flaccid paralysis with convulsions and cognitive decline. mNGS was performed on CSF, urine, plasma, and rectal swab specimens.
The urine sample was positive for JEV RNA.
Seroconversion and PCR analysis confirmed findings.
JEV encephalitis
The patient regained consciousness on day 9 of hospitalization, the limb strength gradually returned. [20] 782 Two samples were determined to be negative for any pathogens.
For HSV-1, C. neoformans and T. gondii, the diagnosis was previously established by standard methods.
The rubella virus uveitis was confirmed by RT-PCR of the aqueous fluid.
A new diagnosis of chronic rubella virus uveitis Clinical outcomes not provided. [47] Clinical outcomes not provided.
[42]
Stool samples positive (n = 22) or negative (n = 5) for Clostridioides (previously Clostridium) difficile were tested by mNGS.
C. difficile was found in 86% of known positive samples by mNGS. Additional pathogens were detected in up to 27% of samples.
Co-detected pathogens were confirmed by PCR.
C. difficile infection
Clinical outcomes not provided. [51] Abbreviations: AST, antimicrobial susceptibility testing BAL, bronchoalveolar lavage; CDC, Centers for Disease Control and Prevention; CFU, colony-forming units; CMV, cytomegalovirus; CSF, cerebrospinal fluid; CVV, Cache Valley virus; EBV, Epstein-Barr virus; ESBL, extended-spectrum β-lactamase; FFPE, formalin-fixed, paraffin-embedded; HHV, human herpesvirus; HSV, herpes simplex virus; IgG, immunoglobulin G; IgM, immunoglobulin M; IVIG, intravenous immunoglobulin; JEV, Japanese encephalitis virus; LRTI, lower respiratory tract infection; mNGS, metagenomic next-generation sequencing; MRI, magnetic resonance imaging; NGS, next-generation sequencing; PCR, polymerase chain reaction; qPCR, quantitative polymerase chain reaction; RSV, respiratory syncytial virus; RT-PCR, reverse-transcription polymerase chain reaction. approaches are being developed for mNGS. A recent example is the use of "spike-in"-based calibration to determine total microbial load as a proxy to convert percentage reads in relation to quantitating bacterial burden in colony-forming units (CFU) per milliliter [26] . Another approach to distinguish colonization from infection is to monitor and assess the host immune response. Langelier et al found that expression of a multigene immune response composite metric was significantly increased in hematopoietic cellular transplant patients with confirmed respiratory pathogens relative to those without a defined pathogen. These results suggest that, even in patients who have significant immunosuppression, the immune response may be used as a biomarker of active infection when utilizing host reads from mNGS analysis of respiratory specimens [19] .
OTHER EXTRANEOUS SOURCES OF NUCLEIC ACID: PROVIDING FURTHER COMPLEXITY TO RESULT INTERPRETATION
The capability of unbiased sequencing directly from patient specimens is what makes mNGS an ideal, hypothesis-free diagnostic tool for infectious diseases. However, it also brings challenges as nucleic acid contamination occurs at several steps in the process from specimen acquisition to specimen processing and the environment, making interpretation of results challenging. Samples should be collected with much caution; for example, lumbar punctures to obtain CSF specimens can be contaminated by normal skin microbiota during the procedure. Similarly, surgical specimens may be contaminated during handling of the biopsy [17] . In addition, specimen collection containers are ideally verified to be DNA/RNA free as they too may serve as a source of contaminating nucleic acid. The development and strict adherence of specimen collection guidelines are crucial for reducing risk of contamination introduced at the time of specimen collection [9] . Furthermore, many researchers have shown that most reagents utilized for mNGS also introduce extraneous, unwanted sources of DNA during the sequencing process; this phenomenon is referred to as the "kit-ome" [9] . A study by Salter et al demonstrated that extraneous DNA is ubiquitous in commonly used DNA extraction reagents and other laboratory reagents used for NGS. The contamination can critically impact results obtained from samples, especially those containing low microbial biomass [27, 28] . This becomes particularly relevant when there is a lack of an obvious pathogen (eg, Mycobacterium tuberculosis or JC virus where they are not found as contaminants in reagents or part of normal microbiota) especially for mNGS analysis of CSF specimens where common reagent contaminants can include members of the Enterobacteriaceae or Cutibacterium acnes (previously known as Propionibacterium acnes), making clinical relevance difficult to discern. Thus, it is imperative that a no-template control (a sample [ie, water or extraction buffer] that is run through the entire mNGS procedure) be included in mNGS analyses to determine the nucleic acid background of the reagents used for sequencing. The no-template control can be used when interpreting results to help filter out contaminating background reads. In fact, the no template control has been utilized as part of a cutoff to determine the relevance of mNGS findings from patient specimens. A recent report used a cutoff of ≥10 ratio of the reads per million sample divided by the reads per million of the no-template control from any given taxon (species, genus, or family) [21] . Another approach is to align the reads to the genome of the pathogen to see if the reads span different areas of the genome. If the reads are localized to a restricted area of the genome, the reads are more likely to represent a contaminant, whereas if the reads span the genome, the organism is more likely to represent a true organism detection [29] .
mNGS METHODS AND VALIDATION IN THE CLINICAL MICROBIOLOGY LABORATORY
Currently, there is no standardized protocol for mNGS. Thus, it is very important for the physician interpreting results to have a good understanding of the scope of the methods being applied as these impact the ability of the assay to detect certain pathogen types and affects interpretation of results. Methods of mNGS can include a DNA-and/or RNA-based approach. If a DNA-based approach is solely applied, pathogen types, except RNA viruses, will be detected. An RNA-based approach is required for detection of RNA viruses and further provides transcriptome-based analysis of other pathogen types and even the host immune response. A DNA approach will indicate what organism(s) are present, but an RNA approach can further reveal what organism(s) are transcriptionally active.
Another major factor that will impact results is the type of extraction method utilized in the laboratory. Nucleic acid recovery may not be equal for all pathogen types [30] . For example, mycobacteria require significant cell wall disruption to efficiently lyse the organisms for nucleic acid release. Different extraction methods may also be required for different specimen types [4] . Efficient extraction methods are a critical step to achieve truly unbiased sequencing of a sample.
In addition, the limit of detection is important to determine, as a negative mNGS result may simply reflect the high leukocyte count of a sample or low sequencing depth of a specimen rather than the absence of a pathogen. The reported limit of detection of mNGS from synthetic CSF matrix varies by organism type from a low of 0.01 CFU/mL for Cryptococcus neoformans, approximately 9 CFU/mL for Klebsiella pneumoniae and Streptococcus agalactiae, 9.4 copies/mL for cytomegalovirus, 55 organisms/mL for Toxoplasma gondii, and 100 copies/mL of human immunodeficiency virus (HIV) type 1, to a high of 130 CFU/mL of Aspergillus niger for detection [4] . This compares to 10 4-5 CFU/mL for detection of pathogens by special stains directly from a specimen (ie, Gram stain), 10 2-3 CFU/mL for growth in culture, and 10-100 CFU/mL for nucleic acid amplification-based methods [31] . It also varies by specimen type, as the limit of detection of mNGS for hepatitis C virus and HIV from plasma has been reported as high as 1 × 10 4 copies/mL, as determined by quantitative PCR [32] . Use of an internal control is extremely important to identify analytic failures and specimens with unusual cellularity that may result in reduced analytical sensitivity. While a negative mNGS result does not completely rule out an infectious process, adequate recovery of the internal control can indicate the level of sensitivity achieved by the assay for that particular sample [4] . Results will still need to be interpreted within a clinical context. Last, validation of mNGS by individual laboratories at the moment can be time consuming and extremely costly, as significant optimization is required for development, and de novo establishment of performance characteristics is required as there are no currently available US Food and Drug Administration (FDA)-cleared methods, instruments, and/or databases [4] . For example, validation of a single specimen type such as CSF will easily require an investment of more than US$100 000 simply for supply costs, not including technologist time and instrumentation fees. Thus, many hospitals may choose to send testing out to larger reference or commercial laboratories that have the resources to optimize and validate mNGS. Regardless of where testing is being performed, physicians need to have a strong understanding of the methods to appropriately interpret the results.
DATA STORAGE, ANALYSIS, AND DATABASES
A major bottleneck of mNGS for infectious disease diagnostics is the ability to decipher the data into clinically relevant information to positively impact patient care. The large sums of data generated by mNGS are burdensome in terms of storage and analysis. mNGS data include host reads, which introduces privacy concerns and requires HIPAA (Health Insurance Portability and Accountability Act)-compliant storage tools [33] . Host reads may be removed during data analysis steps, but can also be helpful to confirm a patient's identity to assist in ruling out mislabeling or contamination issues [34] .
Rapid bioinformatics tools are required to allow for data analysis to obtain clinically actionable results in a meaningful timeframe. A diversity of data analysis tools exist, most of which first filter out host reads and then taxonomically classify the microbial reads to the most accurate taxonomic level (ie, species/ subspecies level if possible, otherwise a genus-, family-, order-, class-, phylum-, or kingdom-level identification is provided) [4] . Two bioinformatics pipelines have been applied successfully in most clinical studies, the "sequence-based ultrarapid pathogen identification" (SURPI or SURPI+) pipeline and the Kraken pipeline [4, 17, 19-23, 29, 35] . Both of these pipelines rapidly align the sequencing reads to the National Center for Biotechnology Information (NCBI) nucleotide reference database and use taxonomic classification for more accurate read assignments [36, 37] . Bioinformatics programs also need to be straightforward with user-friendly interfaces for incorporation into clinical microbiology laboratories. Currently, most of these analytic tools require a significant degree of bioinformatics expertise that is typically not available in clinical laboratories [38] . Some suggest that many different algorithms using a variety of approaches, such as the use of k-mer, marker, and alignments, are required to analyze the data to ensure the highest sensitivity and specificity for taxonomic classification [9, 39] .
Last, curated databases are required as several draft genomes or partial sequences available on NCBI contain erroneous information and can result in false-positive results. False-positive results using noncurated databases can result from low-complexity sequences matching low-quality reads from the sample (ie, computational noise), misannotated species, or contaminants from database entries that also contain reads to human DNA, sequencing adaptors, or vectors. False negatives may occur due to incomplete or lack of taxonomic representation in the databases. Due to these issues, there have been significant efforts put in place to create accurate, regulatory-grade databases, such as the FDA ARGOS database, that can be applied clinically [40] .
TIME TO RESULTS
Currently, the turnaround time for mNGS has been reported to be anywhere from approximately 6 hours to 7 days (average of 48 hours) from specimen receipt depending on the sequencing technology, methods, and bioinformatics programs exploited [9, 22, 25, 41, 42] . In general, mNGS methodologies are labor intensive and require several steps from nucleic acid extraction, library preparation, and sequencing to data analysis. Depending on the sequencing chemistry (read lengths, pairedend vs single-end sequencing, depth of sequencing, or sequencing platforms), it can take up to 48 hours (average of ~ 24 hours) to generate the sequence data alone. Once the sequencing data are generated, rapid bioinformatic pipelines may yield results in as little as 1 hour with significant computational power to support the analysis [17] . mNGS reports can contain >2000 lines in length summarizing the reads from the sample (see Supplementary Data). Figure 3 demonstrates an example of a simplified mNGS Kraken report along with interpretation using a Web-based application tool for visualization of results incorporating heat maps to highlight predominant pathogens and alignment tools useful for result interpretation [29] .
PRECISION MEDICINE TEAM FOR INTERPRETATION OF RESULTS
Perhaps the greatest challenge for the practicing infectious disease clinician is interpretation of the results generated by the sequencing laboratory. Due to the complexity of results generated from mNGS, some institutions have implemented precision medicine teams. These teams consist of representatives from medical microbiology, computational biology, infectious diseases, and other clinician groups who can discuss the results and provide interpretation of the mNGS results prior to reporting. This approach ensures that the most clinically relevant data are reported. Additionally, in the authors' experience, development of such a team was useful in determining direction of assay development and lobbying the institution for resources. Another approach, which is strongly advised, is to have an experienced laboratory director manually review the results prior to release [21] .
SUCCESSFUL APPLICATIONS OF mNGS
mNGS directly from clinical specimens came to the forefront when the Chiu laboratory from the University of California, San Francisco (UCSF) applied the methodology to achieve diagnoses in a case of neuroleptospirosis and a case of neuroinvasive astrovirus [22, 35] . In both cases, standard microbial diagnostic techniques were applied, but no pathogens were identified. Unbiased mNGS was applied and successfully identified the infectious agents in these cases. These cases are examples of the power of NGS as a diagnostic tool.
Initial applications of mNGS for diagnostics focused on central nervous system infections, mostly chronic infections, and have successfully diagnosed rare [22] , novel [43] , and atypical infectious etiologies [23] of encephalitis. One particular case of chronic Cache Valley virus encephalitis in an Australian patient highlights the ability of mNGS to identify pathogens not previously associated with a clinical phenotype [23] . A single report of the accuracy of mNGS compared to standard methods of 84 previously positive CSF specimens and 21 negative specimens observed a diagnostic sensitivity of 84.3% and specificity of 93.7% following discordant analysis [4] . Some recent articles describe the utility of the assay for detection of respiratory pathogens directly from bronchoalveolar lavage specimens from human stem cell transplant and lung transplant recipients [19, 25] . Table 1 summarizes the successful applications of mNGS in the literature to date (July 2017). All these studies have been performed using short read data (second-generation Illumina sequencing), with 2 exceptions. Recently, publications by Pendleton et al and Greninger et al demonstrated the utility of mNGS using the affordable, portable MinION sequencer (third-generation sequencing) that generates long reads with sequencing analysis that can occur in real time [25, 41] . The mNGS analysis of specimens by Pendleton et al resulted in a more rapid turnaround time of the pathogens causing lower respiratory tract infections than standard culture methods [25] . For the most part, the successful application of mNGS has occurred for diagnoses of severe, insidious infections or has been performed in retrospective studies compared to standardof-care results. Ideally, this technology would be applied in real time as an adjunct to current SoC testing.
USE OF mNGS FOR CLINICAL CARE: WHERE ARE WE NOW?
mNGS is currently being offered as a billable laboratory-developed test by both clinical and commercial laboratories. The question is, when should this rather expensive test be considered for clinical care? Based on the available literature, mNGS could be considered when SoC testing is unrevealing and can be used as a last resort effort to try to discern an infectious process. Alternatively, it may be considered for critically ill or severely immunocompromised patients where achieving a timely diagnosis is imperative for improved outcomes. Importantly, mNGS does not replace current SoC methods, but should rather be used as an adjunct to these methods. At this point in time, this question is still actively under investigation and further evidence is required to establish the use of mNGS in routine clinical care.
CONCLUSIONS
mNGS has emerged as a promising single, universal pathogen methodology for infectious disease diagnostics. In addition, mNGS will further be developed in years to come to evaluate antimicrobial resistance genes, strain typing, pathogen evolution, immune response to offending pathogens, and detection of virulence genes. As mNGS methods are still being developed and NGS technologies are rapidly evolving, there are still challenges ahead in terms of data interpretation and patient privacy. Infectious disease clinicians and other treating physicians can actively participate in the quality management of NGS diagnostic applications by appreciating the complexities and nuances of the methodologies being applied and ensuring that steps, as discussed in this and other reviews, are implemented to generate meaningful results beneficial to patient care.
Supplementary Data
Supplementary materials are available at Clinical Infectious Diseases online. Consisting of data provided by the authors to benefit the reader, the posted materials are not copyedited and are the sole responsibility of the authors, so questions or comments should be addressed to the corresponding author.
Note
Potential conflicts of interest. K. C. C. reports grants from Accelerate Diagnostics, Curetis, BD Diagnostics, and GenePOC; personal fees from Roche Molecular, McGraw-Hill, American Society for Microbiology, and Elsevier. P. J. S. reports grants from Accelerate Diagnostics, BD Diagnostics, bioMérieux, Cellex, Check-Points Diagnostics, BV, and Hardy Diagnostics; and personal fees from the American Society for Microbiology and Accelerate Diagnostics. S. M. has a patent for the SURPI pipeline issued to UCSF, a patent for microbial standard reference materials for pathogen detection pending to UCSF, and a patent for historic contaminant database for mNGS applications pending to UCSF. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.
